280 related articles for article (PubMed ID: 12962951)
1. Reduced perception of urgency in treatment of overactive bladder with extended-release tolterodine.
Freeman R; Hill S; Millard R; Slack M; Sutherst J;
Obstet Gynecol; 2003 Sep; 102(3):605-11. PubMed ID: 12962951
[TBL] [Abstract][Full Text] [Related]
2. Efficacy, safety, and tolerability of extended-release once-daily tolterodine treatment for overactive bladder in older versus younger patients.
Zinner NR; Mattiasson A; Stanton SL
J Am Geriatr Soc; 2002 May; 50(5):799-807. PubMed ID: 12028164
[TBL] [Abstract][Full Text] [Related]
3. Tolterodine once-daily: superior efficacy and tolerability in the treatment of the overactive bladder.
Van Kerrebroeck P; Kreder K; Jonas U; Zinner N; Wein A;
Urology; 2001 Mar; 57(3):414-21. PubMed ID: 11248608
[TBL] [Abstract][Full Text] [Related]
4. Clinical efficacy and tolerability of extended-release tolterodine and immediate-release oxybutynin in Japanese and Korean patients with an overactive bladder: a randomized, placebo-controlled trial.
Homma Y; Paick JS; Lee JG; Kawabe K;
BJU Int; 2003 Nov; 92(7):741-7. PubMed ID: 14616458
[TBL] [Abstract][Full Text] [Related]
5. Which anticholinergic drug for overactive bladder symptoms in adults.
Madhuvrata P; Cody JD; Ellis G; Herbison GP; Hay-Smith EJ
Cochrane Database Syst Rev; 2012 Jan; 1():CD005429. PubMed ID: 22258963
[TBL] [Abstract][Full Text] [Related]
6. Treatment of urge-predominant mixed urinary incontinence with tolterodine extended release: a randomized, placebo-controlled trial.
Khullar V; Hill S; Laval KU; Schiøtz HA; Jonas U; Versi E
Urology; 2004 Aug; 64(2):269-74; discussion 274-5. PubMed ID: 15302476
[TBL] [Abstract][Full Text] [Related]
7. Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial.
Kaplan SA; Roehrborn CG; Rovner ES; Carlsson M; Bavendam T; Guan Z
JAMA; 2006 Nov; 296(19):2319-28. PubMed ID: 17105794
[TBL] [Abstract][Full Text] [Related]
8. Tolterodine: a safe and effective treatment for older patients with overactive bladder.
Malone-Lee JG; Walsh JB; Maugourd MF
J Am Geriatr Soc; 2001 Jun; 49(6):700-5. PubMed ID: 11454106
[TBL] [Abstract][Full Text] [Related]
9. Prospective randomized controlled trial of extended-release oxybutynin chloride and tolterodine tartrate in the treatment of overactive bladder: results of the OBJECT Study.
Appell RA; Sand P; Dmochowski R; Anderson R; Zinner N; Lama D; Roach M; Miklos J; Saltzstein D; Boone T; Staskin DR; Albrecht D;
Mayo Clin Proc; 2001 Apr; 76(4):358-63. PubMed ID: 11322350
[TBL] [Abstract][Full Text] [Related]
10. Comparison of fesoterodine and tolterodine extended release for the treatment of overactive bladder: a head-to-head placebo-controlled trial.
Herschorn S; Swift S; Guan Z; Carlsson M; Morrow JD; Brodsky M; Gong J
BJU Int; 2010 Jan; 105(1):58-66. PubMed ID: 20132103
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and tolerability of tolterodine extended-release in men with overactive bladder and urgency urinary incontinence.
Roehrborn CG; Abrams P; Rovner ES; Kaplan SA; Herschorn S; Guan Z
BJU Int; 2006 May; 97(5):1003-6. PubMed ID: 16643482
[TBL] [Abstract][Full Text] [Related]
12. Tolterodine extended release improves overactive bladder symptoms in men with overactive bladder and nocturia.
Kaplan SA; Roehrborn CG; Dmochowski R; Rovner ES; Wang JT; Guan Z
Urology; 2006 Aug; 68(2):328-32. PubMed ID: 16904446
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of fesoterodine compared with extended-release tolterodine in men and women with overactive bladder.
Ginsberg D; Schneider T; Kelleher C; Van Kerrebroeck P; Swift S; Creanga D; Martire DL
BJU Int; 2013 Aug; 112(3):373-85. PubMed ID: 23826844
[TBL] [Abstract][Full Text] [Related]
14. Randomized, double-blind placebo- and tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder.
Chapple CR; Rechberger T; Al-Shukri S; Meffan P; Everaert K; Huang M; Ridder A;
BJU Int; 2004 Feb; 93(3):303-10. PubMed ID: 14764127
[TBL] [Abstract][Full Text] [Related]
15. Tolterodine, a new antimuscarinic agent: as effective but better tolerated than oxybutynin in patients with an overactive bladder.
Abrams P; Freeman R; Anderström C; Mattiasson A
Br J Urol; 1998 Jun; 81(6):801-10. PubMed ID: 9666761
[TBL] [Abstract][Full Text] [Related]
16. Prospective, randomized, double-blind study of the efficacy and tolerability of the extended-release formulations of oxybutynin and tolterodine for overactive bladder: results of the OPERA trial.
Diokno AC; Appell RA; Sand PK; Dmochowski RR; Gburek BM; Klimberg IW; Kell SH;
Mayo Clin Proc; 2003 Jun; 78(6):687-95. PubMed ID: 12934777
[TBL] [Abstract][Full Text] [Related]
17. Tolterodine: a review of its use in the treatment of overactive bladder.
Clemett D; Jarvis B
Drugs Aging; 2001; 18(4):277-304. PubMed ID: 11341475
[TBL] [Abstract][Full Text] [Related]
18. Which anticholinergic drug for overactive bladder symptoms in adults.
Hay-Smith J; Herbison P; Ellis G; Morris A
Cochrane Database Syst Rev; 2005 Jul; (3):CD005429. PubMed ID: 16034974
[TBL] [Abstract][Full Text] [Related]
19. Comparison of fesoterodine and tolterodine in patients with overactive bladder.
Chapple CR; Van Kerrebroeck PE; Jünemann KP; Wang JT; Brodsky M
BJU Int; 2008 Nov; 102(9):1128-32. PubMed ID: 18647298
[TBL] [Abstract][Full Text] [Related]
20. Tolterodine extended release is efficacious in continent and incontinent subjects with overactive bladder.
Rovner ES; Rackley R; Nitti VW; Wang JT; Guan Z;
Urology; 2008 Sep; 72(3):488-93. PubMed ID: 18639327
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
